By Blood Cancers Today Staff Writers - Last Updated: February 8, 2024
Selinexor (Xpovio®) has been added to China’s National Reimbursement Drug List (2023 Version; NRDL) for the treatment of adult patients with relapsed or refractory multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody.
The updated NRDL took effect on January 1, 2024, according to a press release from the manufacturer of the drug, Antengene Corporation Limited.
“Antengene is committed to ensuring that our innovative treatments are delivered swiftly to myeloma patients across China, with improved affordability and accessibility, as a result of [the inclusion of Xpovio in the] NRDL,” said Jay Mei, MD, PhD, Antengene’s founder, Chairman, and Chief Executive Officer. “Moving forward, Antengene remains steadfast and focused on our vision of ‘treating patients beyond borders.’ We are determined to expand the use of Xpovio to additional indications, fully realizing its therapeutic potential and contributing to the continuous improvement of health outcomes for patients in China.”
Original Source: Selinexor Added to China’s National Reimbursement Drug List | Blood Cancers Today